Skip to Content

IMGN529 Approval Status

IMGN529 is a CD37-targeting Antibody-Drug Conjugate (ADC) in development for the treatment of non-Hodgkin's Lymphoma and other B-cell malignancies.

Development Status and FDA Approval Process for IMGN529

Dec  6, 2014ImmunoGen, Inc. Announces Encouraging IMGN529 Clinical Data Presented at 56th ASH Annual Meeting and Exposition
Sep 23, 2011ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.